PT3247340T - Expressão induzida de fator neurotrófico derivado de cérebro (bdnf) para o tratamento de doenças neuromusculares, neurodegenerativas, autoimunes, do desenvolvimento e/ou metabólicas - Google Patents
Expressão induzida de fator neurotrófico derivado de cérebro (bdnf) para o tratamento de doenças neuromusculares, neurodegenerativas, autoimunes, do desenvolvimento e/ou metabólicasInfo
- Publication number
- PT3247340T PT3247340T PT167034099T PT16703409T PT3247340T PT 3247340 T PT3247340 T PT 3247340T PT 167034099 T PT167034099 T PT 167034099T PT 16703409 T PT16703409 T PT 16703409T PT 3247340 T PT3247340 T PT 3247340T
- Authority
- PT
- Portugal
- Prior art keywords
- bdnf
- neuromuscular
- developmental
- neurodegenerative
- autoimmune
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- 101150035467 BDNF gene Proteins 0.000 title 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 title 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 title 1
- 208000012239 Developmental disease Diseases 0.000 title 1
- 230000001363 autoimmune Effects 0.000 title 1
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 title 1
- 208000030159 metabolic disease Diseases 0.000 title 1
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
- 230000000626 neurodegenerative effect Effects 0.000 title 1
- 230000002232 neuromuscular Effects 0.000 title 1
- 208000018360 neuromuscular disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
- A61K31/06—Phenols the aromatic ring being substituted by nitro groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562106365P | 2015-01-22 | 2015-01-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3247340T true PT3247340T (pt) | 2023-10-31 |
Family
ID=55310938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT167034099T PT3247340T (pt) | 2015-01-22 | 2016-01-21 | Expressão induzida de fator neurotrófico derivado de cérebro (bdnf) para o tratamento de doenças neuromusculares, neurodegenerativas, autoimunes, do desenvolvimento e/ou metabólicas |
Country Status (13)
| Country | Link |
|---|---|
| US (6) | US9763896B2 (enExample) |
| EP (1) | EP3247340B1 (enExample) |
| JP (3) | JP6951976B2 (enExample) |
| KR (1) | KR102690198B1 (enExample) |
| CN (2) | CN116617195A (enExample) |
| AU (2) | AU2016209255B2 (enExample) |
| BR (1) | BR112017015721A2 (enExample) |
| CA (1) | CA2974092A1 (enExample) |
| ES (1) | ES2961334T3 (enExample) |
| HK (1) | HK1247101A1 (enExample) |
| MX (2) | MX392410B (enExample) |
| PT (1) | PT3247340T (enExample) |
| WO (1) | WO2016118741A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016209255B2 (en) | 2015-01-22 | 2021-07-01 | Mitochon Pharmaceuticals, Inc. | Induced expression of brain derived neurotrophic factor (BDNF) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases |
| WO2018129258A1 (en) | 2017-01-06 | 2018-07-12 | Gencia Corporation | Novel phenyl derivatives |
| EP3576739A2 (en) * | 2017-01-31 | 2019-12-11 | Paolo L. Manfredi | Compounds for treatment or prevention of disorders of the nervous system and symptoms and manifestations thereof, and for cyto-protection against diseases and aging of cells, and symptoms and manifestations thereof |
| US10660879B2 (en) | 2017-06-23 | 2020-05-26 | Enzo Biochem, Inc. | Sphingosine pathway modulating compounds for the treatment of cancers |
| US10675255B2 (en) | 2017-06-23 | 2020-06-09 | Enzo Bochem, Inc. | Sphingosine pathway modulating compounds for the treatment of cancers |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| CN116437942A (zh) * | 2020-09-29 | 2023-07-14 | Cefo有限公司 | 包含manf的用于预防或治疗神经精神性疾病的组合物 |
| WO2023205625A2 (en) * | 2022-04-18 | 2023-10-26 | Mitochon Pharmaceuticals, Inc. | 2,4 dnp and prodrugs thereof for treatment of pulmonary and autoimmune diseases |
| WO2025051360A1 (en) * | 2023-09-06 | 2025-03-13 | Instituto de Medicina Molecular João Lobo Antunes | Trkb-t1 agonist for the treatment of absence seizure and/or comorbidities |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6664297B1 (en) * | 2000-10-18 | 2003-12-16 | Universidade Federal Do Rio De Janeiro | Methods for inhibition and dissolution of amyloidoses by administration of compositions comprising 2,4-dinitrophenol |
| US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| EP1764095A1 (en) * | 2005-09-20 | 2007-03-21 | Revotar Biopharmaceuticals AG | Novel nitrocatechol derivatives having selectin ligand activity |
| EP2170338A2 (en) * | 2007-07-06 | 2010-04-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Dna-pkcs modulates energy regulation and brain function |
| JP6706204B2 (ja) | 2013-08-30 | 2020-06-03 | イエール ユニバーシティ | 新規２，４−ジニトロフェノール製剤およびその使用法 |
| AU2016209255B2 (en) * | 2015-01-22 | 2021-07-01 | Mitochon Pharmaceuticals, Inc. | Induced expression of brain derived neurotrophic factor (BDNF) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases |
-
2016
- 2016-01-21 AU AU2016209255A patent/AU2016209255B2/en active Active
- 2016-01-21 BR BR112017015721A patent/BR112017015721A2/pt not_active Application Discontinuation
- 2016-01-21 EP EP16703409.9A patent/EP3247340B1/en active Active
- 2016-01-21 ES ES16703409T patent/ES2961334T3/es active Active
- 2016-01-21 MX MX2017009402A patent/MX392410B/es unknown
- 2016-01-21 HK HK18106712.4A patent/HK1247101A1/zh unknown
- 2016-01-21 CN CN202211548767.9A patent/CN116617195A/zh active Pending
- 2016-01-21 PT PT167034099T patent/PT3247340T/pt unknown
- 2016-01-21 KR KR1020177023034A patent/KR102690198B1/ko active Active
- 2016-01-21 WO PCT/US2016/014312 patent/WO2016118741A1/en not_active Ceased
- 2016-01-21 US US15/002,531 patent/US9763896B2/en active Active
- 2016-01-21 JP JP2017539363A patent/JP6951976B2/ja active Active
- 2016-01-21 CN CN201680017379.4A patent/CN107405315A/zh active Pending
- 2016-01-21 CA CA2974092A patent/CA2974092A1/en active Pending
- 2016-11-21 US US15/357,412 patent/US9974755B2/en active Active
-
2017
- 2017-07-18 MX MX2022005937A patent/MX2022005937A/es unknown
- 2017-09-18 US US15/707,239 patent/US10220006B2/en active Active
-
2019
- 2019-01-17 US US16/250,470 patent/US10864173B2/en active Active
-
2020
- 2020-11-09 US US17/093,193 patent/US11717497B2/en active Active
-
2021
- 2021-03-01 JP JP2021031635A patent/JP7440092B2/ja active Active
- 2021-09-27 AU AU2021240120A patent/AU2021240120A1/en not_active Abandoned
-
2022
- 2022-10-03 JP JP2022159466A patent/JP2022173519A/ja active Pending
-
2023
- 2023-06-16 US US18/336,440 patent/US20240156750A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT3247340T (pt) | Expressão induzida de fator neurotrófico derivado de cérebro (bdnf) para o tratamento de doenças neuromusculares, neurodegenerativas, autoimunes, do desenvolvimento e/ou metabólicas | |
| IL282655A (en) | Methods of treating developmental disorders using pipradrol | |
| IL259281B (en) | History of bipyrazolyl used in the treatment of autoimmune diseases | |
| IL269106A (en) | Methods for the treatment of neurodegenerative diseases | |
| PL3419622T3 (pl) | Leczenie neurodegeneracyjnej choroby oczu przy użyciu pridopidyny | |
| PL3393579T3 (pl) | Układ do leczenia oczu | |
| GB201516905D0 (en) | Treatment of Neurodegenerative diseases | |
| IL269604A (en) | Pentides for the treatment of autoimmune diseases | |
| IL254155A0 (en) | pain treatment | |
| LT3727423T (lt) | Metabolinių sutrikimų gydymas fgf21 variantais | |
| GB201714307D0 (en) | Treatment of neurodegenerative diseases | |
| EP3271017A4 (en) | Treatment of skin conditions | |
| GB201601456D0 (en) | Improvements relating to retinal treatment | |
| ZA202002910B (en) | Treatment of skin disorders | |
| GB201714311D0 (en) | Treatment of neurodegenerative diseases | |
| GB201714303D0 (en) | Treatment of neurodegenerative diseases | |
| GB201710109D0 (en) | Albumin-based therapeutic molecules | |
| GB201710105D0 (en) | Albumin-based therapeutic molecules | |
| GB201704666D0 (en) | Treatment of neurodegenerative diseases | |
| GB201514909D0 (en) | Treatment of autoimmune diseases | |
| GB201703768D0 (en) | Skin treatment methods | |
| GB201703734D0 (en) | Skin treatment methods | |
| EP3116507A4 (en) | Treatment of brain and central nervous system tumors | |
| GB201522706D0 (en) | Treatments of central nervous system conditions | |
| GB201522257D0 (en) | Treatment of autism |